Journal Articles

Donald and Barbara Zucker School of Medicine
Academic Works

2015

Effects of Parvovirus B19 Infection in Renal
Transplant Recipients: A Retrospective Review of
Three Cases
P. Krishnan
P. Ramadas
P. P. Rajendran
P. Madhavan
A. Alex
See next page for additional authors

Follow this and additional works at: https://academicworks.medicine.hofstra.edu/articles
Part of the Surgery Commons
Recommended Citation
Krishnan P, Ramadas P, Rajendran P, Madhavan P, Alex A, Jayaschandran V, Humayun S, Ali N, Sachdeva M, Flecha A, Basu A,
Bhaskaran M, Molmenti EP. Effects of Parvovirus B19 Infection in Renal Transplant Recipients: A Retrospective Review of Three
Cases. . 2015 Jan 01; 24(2):Article 1887 [ p.]. Available from: https://academicworks.medicine.hofstra.edu/articles/1887. Free full
text article.

This Article is brought to you for free and open access by Donald and Barbara Zucker School of Medicine Academic Works. It has been accepted for
inclusion in Journal Articles by an authorized administrator of Donald and Barbara Zucker School of Medicine Academic Works. For more
information, please contact academicworks@hofstra.edu.

Authors

P. Krishnan, P. Ramadas, P. P. Rajendran, P. Madhavan, A. Alex, V. Jayaschandran, S. G. Humayun, N. Ali, M.
Sachdeva, A. Flecha, A. Basu, M. Bhaskaran, and E. P. Molmenti

This article is available at Donald and Barbara Zucker School of Medicine Academic Works:
https://academicworks.medicine.hofstra.edu/articles/1887

Original Article

87

Effects of Parvovirus B19 Infection in Renal
Transplant Recipients: A Retrospective Review of
Three Cases

1 Department of Transplant Program, North Shore University Hospital,

Boulevard, Manhasset, New York
2 Department of Anesthesiology, Brookdale University Hospital and
Medical Center, Boulevard, Manhasset, New York
3 Department of Nephrology, North Shore University Hospital,
Boulevard, Manhasset, New York

Address for correspondence Madhu Bhaskaran, MD, NSUH-Transplant
Center, 1554 Northern Boulevard, Manhasset, New York 11030
(e-mail: mbhaskar@nshs.edu).

Int J Angiol 2015;24:87–92.

Abstract

Keywords

►
►
►
►

allograft
anemia
immunosuppression
intravenous
immunoglobulin
► parvovirus B19
► renal transplant

Parvovirus B19 (PVB19) is a DNA virus which causes clinically relevant infection in renal
transplant recipients (RTR) leading to signiﬁcant morbidity. Manifestations include
erythropoietin resistant anemia, proteinuria, and glomerulosclerosis in the allograft.
Severe infection may require administration of intravenous immunoglobulin, reduction
in immunosuppression and transfusions. The major challenge in managing and
preventing the infection in RTR involves the act of balancing the decreased level of
immunosuppression and the risk of rejection. The objective of this article is to
understand the importance of PVB19 infection and its outcome in RTR. We reviewed
the medical records of three RTR with conﬁrmed PVB19 infection and recorded patient
information including demographics, clinical and laboratory data, management, and
outcome. The average time of occurrence of PVB19 infection as transplant was 8.6
weeks and they presented with symptomatic anemia. Elevated creatinine values were
noted in two of them. Following treatment, anemia improved and creatinine values
returned to baseline. One of them developed an early relapse and had to be treated once
again similarly. We emphasize the importance of maintaining a high index of suspicion
for PVB19 infection in patients with anemia in the posttransplant phase, especially in
patients on higher doses of immunosuppressants. Early and proper treatment can
prevent worsening clinical condition and possible effects on the allograft.

Parvovirus B19 (PVB19) is a nonenveloped DNA virus which is
a ubiquitous human pathogen, primarily spread via respiratory droplets. The infection can be symptomatic or asymptomatic according to the host’s age and immunologic status.
The natural course of the infection in immunosuppressed
individuals such as renal transplant recipients (RTR) are

varied.1 Although anemia is the most common manifestation,2 PVB19 can also cause pancytopenia, hepatitis, myocarditis, neurological disease,1,3,4 and allograft dysfunction.5
Transmission can occur to the recipient from the allograft
itself, as the virus may persist for years in seropositive
individuals.6 Therefore, it may be relevant to screen selected
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Table 1 General information of the recipients and donors
Patient 1

Patient 2

Patient 3

Age (y)

58

44

30

Gender

M

F

M

Comorbidities

DM, HTN

HTN

HTN

Cause of ESRD

DM, HTN

Obstructive uropathy

Chronic glomerulonephritis

Year of transplant

2013

2010

2008

Age of donor (y)

23

41

22

Type of donor

Live

Live

Live

HLA mismatches

5/6

6/6

5/6

Induction protocol

Basiliximab, steroid

Basiliximab, steroid

Basiliximab, steroid

Immunosuppression protocol

Tacrolimus, MMF, prednisone

Tacrolimus, MMF,
prednisone

Tacrolimus, MMF, prednisone

Acute rejection

Acute cellular rejection at
2 weeks posttransplant, conﬁrmed
with biopsy, treated with pulse
IV Solumedrol

No

No

Baseline creatinine (mg/dL)

1.3

1.12

1.2

Abbreviations: DM, diabetes mellitus; ESRD, end-stage renal disease; F, female; HLA, human leukocyte antigen; HTN, hypertension; M, male; MMF,
mycophenolate mofetil.

donors for PVB19 and monitor for possible manifestations
such as resistant anemia in RTR. The major challenge in
managing and preventing PVB19 infection in RTR involves
the act of balancing the decreased level of immunosuppression and the risk of rejection.

Patients and Methods
We retrospectively reviewed the medical records of 144 RTR
who were followed up at a tertiary care hospital afﬁliated
transplant program from January 2007 to June 2013 and
selected three patients with conﬁrmed PVB19 infection. The
maintenance immunosuppression protocol that was followed
consisted of tacrolimus, mycophenolate mofetil, and prednisone. These patients presented with anemia in the posttransplant period, and were subsequently diagnosed with PVB19
infection. We collected patient information including demographics, clinical, and laboratory data. The detection of
infection was done by polymerase chain reaction (PCR) or
immunoglobulin M (IgM) serology of blood samples or bone
marrow study indicative of PVB19. The management and
outcome was also recorded. The study has been approved by
the Institutional Review Board at the hospital.

Results
Of 144 RTR, there were 3 cases (2%) of PVB19 infection. All
recipients had normal baseline creatinine posttransplant. The
average time for detection of PVB19 infection since transplant
was 8.6 weeks and they presented with symptomatic anemia.
The lowest hemoglobin (Hb) value noted was 6 mg/dL.
Epstein-Barr virus and cytomegalovirus were the associated
coinfections. Elevated creatinine values were noted in two of
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them. Following treatment, anemia improved and creatinine
values returned to baseline. Sustained improvement in Hb
was seen after 4 weeks in two of them and after 12 weeks in
the third patient. One of them developed an episode of
recurrence.
Refer to ►Tables 1 to 3 for details regarding patient
characteristics, presentation and investigations, treatment
and outcome, respectively.
Refer to ►Fig. 1 for graph showing variations in Hb of the
three patients and ►Fig. 2 showing variations in creatinine
values of the three patients.

Discussion
RTR are highly susceptible to infections such as PVB197
because of the increased use of induction therapy to prevent
early acute rejection and because of the effect of sustained
long-term immunosuppression to prevent chronic rejection.
A study in 2006 identiﬁed that the median time for
occurrence of PVB19 infection after transplantation was
around 1.75 months, with majority of the cases occurring
within 3 months posttransplant.5
Chronic anemia is well-recognized complication in approximately 39% of RTR, with erythropoietin-resistant anemia occurring in almost 9% of them.8 PVB19 is capable of
targeting erythroid progenitor cells in the bone marrow
leading to a cessation in erythropoiesis. This usually reverts
back to normal by the production of antibodies against the
virus in immunocompetent individuals. However in RTR, such
infections often lead to persistent pure red cell aplasia with
normal white cell and platelet counts.8 Studies suggest that
nearly 23% of RTR with persistent anemia had positive PCR
values for PVB19.8
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Patient 1

Patient 2

Patient 3

Time of parvovirus
infection posttransplant

8 wk

7 wk

11 wk

Presentation

Dizziness, dyspnea on exertion, dark stools

Dizziness, dark stools

Dizziness, dyspnea on exertion, palpitation

Physical exam

HR, 89; BP, 134/74; RR, 18;
Temp, 98, SpO2, 96%

HR, 100; BP, 130/54; RR, 18,
Temp, 98.6; SpO2, 98%

HR, 86; BP,110/68; RR,18;
Temp, 98.4; SpO2, 98%

Investigations: blood

Hb, 6.6; Hct, 19.6; RBC count,
2.34; TC, 4,600; Plt, 295, RBC
indices, normal

Hb, 7.1; Hct, 21.2; RBC count,
2.31; TC, 6,300; Plt, 419; RBC
indices, normal

Hb, 6.3; Hct, 18.4; RBC count,
2.22; TC, 4,600; Plt, 320; RBC
indices, normal

Reticulocyte count, 0.3%

Reticulocyte count, 0.2%

Reticulocyte count, 0.2%

RBS, 230; Na, 140; K, 4.1; Cl,
106; HCO3, 21

RBS, 86; Na, 137; K,4.5; Cl,
105; HCO3, 20

RBS, 113; Na, 130; K,4.7; Cl,
100; HCO3, 21

Others

BUN/Cr, 31/1.51

BUN/Cr, 20/1.27

BUN/Cr, 13/1.1

LDH, 134

LDH, 188

LDH, 144

Iron studies-increased iron and
ferritin, decreased TIBC

Iron studies-normal iron, increased ferritin, decreased
TIBC

Iron studies-increased iron and
ferritin, decreased TIBC

Haptoglobin, normal; B12 and
folate, normal

Haptoglobin, normal; B12 and
folate, normal

Haptoglobin, normal; B12 and
folate, normal

Urinalysis, no proteinuria

Urinalysis, no proteinuria

Urinalysis, no proteinuria

FOB, negative

FOB, positive

Not indicated

CT abdomen-no evidence of
bleeding

CT abdomen-no evidence of
bleeding

CT abdomen-no evidence of
bleeding

OGD-erosive gastropathy

OGD-normal

Not indicated

Colonoscopy- normal

Colonoscopy-pan colitis

Not indicated

Initial management

Aspirin stopped and patient
monitored for bleeding.
In spite of no active bleeding,
Hb continued to drop rapidly
and Parvovirus infection was
suspected

Treated conservatively for colitis, no further bleeding but
Hb continued to drop, BMA
done and showed erythroid
aplasia. Renal biopsy was done
due to rise in creatinine and it
showed hydropic changes in
tubular epithelial cells

Hb continued to drop, BMA
done which showed erythroid
aplasia.

Detection of parvovirus

Positive PCR

Bone marrow study, positive
PCR

Positive PCR, positive IgM serology, bone marrow study

Co infections

CMV PCR positive, EBV antigen
positive

EBV antigen positive

CMV PCR positive

Lowest Hb level
after diagnosis

6

6.2

6

Highest Cr level
after diagnosis

1.74

2.25

1.3

Abbreviations: BP, blood pressure (mm Hg); BMA, bone marrow aspiration; BUN, blood urea nitrogen (mg/dL); Cl, chloride (mEq/L); CMV,
cytomegalovirus; Cr, creatinine (mg/dL); EBV, Epstein-Barr virus; FOB, fecal occult blood; Hb, hemoglobin (g/dL); HCO3, bicarbonate (mEq/L); Hct,
hematocrit (%); HR, heart rate (no of beats/min); K, potassium (mEq/L); LDH, lactate dehydrogenase (IU/L); Na, sodium (mEq/L); OGD,
esophagoduodenoscopy; PCR, polymerase chain reaction; Plt, platelet; RBS, random blood sugar (mg/dL); RBC, red blood cells; RR, respiratory rate
(per min); TC, total count; Temp, temperature (°F); TIBC, total iron binding capacity.

Immunosuppression is the major risk factor for the infection in RTR, indicated by improvement in anemia when
immunosuppression is decreased.9 Induction with antithymocyte globulin is found to have a higher risk for the infection
compared with basiliximab.10 Substitution of tacrolimus with

cyclosporine was also followed by viral clearance and resolution of anemia.9,11 Vigilance should be observed during highrisk periods such as early after transplantation and after
treatment for rejection, when the dose of immunosuppressants are high.4
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Table 3 Treatment and outcome of the patients
Patient 1

Patient 2

Patient 3

Treatment

IVIG infusion, decreased
immunosuppression, 3
units PRBC transfusion

IVIG infusion, decreased
immunosuppression, 4
units PRBC transfusion

IVIG infusion, decreased
immunosuppression, 2
units PRBC transfusion

Hb posttreatment (g/dL)

12.1

13.1

11.5

Cr posttreatment (mg/dL)

1.19

1.15

1.3

Sustained Hb improvement

After 4 wk

After 4 wk

After 12 wk

Recurrences

No

No

Yes, one recurrence. treated
similarly

Allograft dysfunction

Transient

Transient

No

Outcome

Anemia resolved, no allograft dysfunction, viral titers
decreased on follow-up, patient is still on routine immunosuppression protocol
because of his history of
acute rejection

Anemia resolved, no allograft dysfunction, viral serology became negative on
follow-up. Patient is on a
reduced dose of immunosuppression as the infection

Anemia resolved, no allograft dysfunction, viral IgM
serology became negative.
Patient is on a reduced dose
of immunosuppression
since the infection

Abbreviations: Cr, creatinine; Hb, hemoglobin; IgM, immunoglobulin M; IVIG, intravenous immunoglobulin; PRBC, packed red blood cells.

Coinfection of PBV19 and other viruses such as cytomegalovirus and with human herpes virus 6 have also been
reported.12
Detection of PVB19 can be done via molecular techniques
or by measurement of viral antibodies. IgM assays will detect
a recent infection,13 but it is less reliable due to delayed or
inadequate humoral response.14 Viral DNA can be detected in
blood, bone marrow, and infected organs using PCR15 and is
also detected in asymptomatic individuals.16 However, the

Fig. 1 Graph showing variations in hemoglobin of the three patients.
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detection of viral DNA with clinical ﬁndings is likely to
represent active infection. If serology and PCR are negative
but the clinical suspicion is high, examination of bone marrow specimen using immunohistochemical staining or in situ
hybridization is helpful in establishing the diagnosis.5
The main histopathological pictures of PVB19 infection of
allograft kidney are thrombotic microangiopathy and collapsing glomerulopathy.17–19 Reports have shown an elevation of
plasma creatinine and proteinuria.20
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Fig. 2 Graph showing variations in creatinine values of the three patients.

The treatment of PBV19 is reduction of immunosuppression
and intravenous immunoglobulin (IVIG) administration.21 It is
also important to avoid the use of erythropoietin to combat the
anemia while treating PVB19, as this can lead to a resistance of
the virus to proven treatment.22

2 Eid AJ, Chen SF; AST Infectious Diseases Community of Practice.

Conclusion

4

PVB19 is an important treatable cause of anemia in RTR. A
high index of suspicion should be maintained in patients with
anemia in the posttransplant phase, especially those who
have received higher doses of immunosuppressants. It may be
relevant to screen-selected donors for asymptomatic PVB19
infection and to keep an eye out for anemia in RTR if the donor
has the infection. Further studies on a larger sample are
required to determine whether recommendations for routine
donor screening need to be made. Early diagnosis and appropriate intervention can minimize the negative impacts of the
infection.
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